Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ABT-869

A substance being studied in the treatment of several types of cancer. ABT-869 blocks the action of several growth factors. It may also block the growth of new blood vessels that tumors need to grow and may cause cancer cells to die. It is a type of receptor tyrosine kinase inhibitor and a type of angiogensis inhibitor. Also called multitargeted receptor tyrosine kinase inhibitor ABT-869.

ABT-869

Search NCI's Dictionary of Cancer Terms